Differences between Dietary Supplement and Prescription Drug Omega-3 Fatty Acid Formulations: A Legislative and Regulatory Perspective

REFERENCES

• The Medical Letter on Drugs and Therapeutics:Vitamin Supplements.1213 :57– 58,2005 .
   Google Scholar
• Miller E, Pastor-Barriero R: Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality.Ann Intern Med142 :37– 46,2005 .
   PubMed Web of Science ®Google Scholar
• Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group: The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers.N Engl J Med330 :1029– 1035,1994 .
   PubMed Web of Science ®Google Scholar
• Omenn G, Goodman G, Thornquist M, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL, Valanis B, Williams JH, Barnhart S, Hammar S: Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease.N Engl J Med334 :1150– 1155,1996 .
   PubMed Web of Science ®Google Scholar
• Feskanich D, Singh V, Willett W, Colditz G: Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia.JAMA287 :47– 54,2002 .
   PubMed Web of Science ®Google Scholar
• Office of Nutritional Products, Labeling, and Dietary Supplements, Center for Food Safety and Applied Nutrition, US Food and Drug Administration:Letter responding to a request to reconsider the qualified claim for a dietary supplement health claim for omega-3 fatty acids and coronary heart disease. Docket No. 91N-0103.
   Google Scholar
• Kris-Etherton P, Harris W, Appel L, American Heart Association (AHA), AHA Nutrition Committee: Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease.Circulation106 :2747– 2757,2002 .
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline, Inc. Data on File, Research Triangle Park, NC 27708.
   Google Scholar
• LOVAZA [package insert], Research Triangle Park, NC. GlaxoSmithKline Pharmaceuticals, Inc.2008 .
   Google Scholar
• USFDA: FDA News:FDA Announces Qualified Health Claims for Omega-3 Fatty Acids.2004 ; September 8, 2004:1– 2.
   Google Scholar
• USFDA: FDA overview: dietary supplements, infant formulas, cosmetics. Available at http://www.emedicinehealth.com/script/main/art.asp?articlekey=59287&pf=3&page6 Accessed March 7,2006 .
   Google Scholar
• FDA/CFSAN:Dietary Supplement Health and Education Act of 1994. U.S. Food and Drug Administration Center for Food Safety and Applied Nutrition, December 1,1995 . Available at http://www.cfsan.fda.gov/∼dms/dietsupp.html Accessed March 3, 2007.
   Google Scholar
• U.S. Food and Drug Administration: FDA Issues Dietary Supplements Final Rule. FDA News. Available at http://www.fda.gov/bbs/topics/NEWS/2007/NEW01657.html Accessed June 29, 2007.
   Google Scholar
• Food and Drug Administration: Compliance Program and Guidance Manual: Active Pharmaceutical ingredient (API) Process Inspection. Revision Summary. FDA: Form FDA 2438g (electronic-09/2003). Available at: http://www.fda.gov/cder/dmpq/7356-002f-CDER.pdf Accessed March 1, 2007.
   Google Scholar
• FDA Backgrounder: Milestones in U.S. food and drug law history. May 3, 1999, updated August 2005. Available online at http://www.fda.gov/opacom/backgrounders/miles.html Accessed March 2,2006 .
   Google Scholar
• Dietary Supplement Health and Education Act of 1994, Public Law 103–417, 103rd Congress: Available at http://www.fda.gov/opacom/laws/dshea.html Accessed March 3,2006 .
   Google Scholar
• Dostalek M, Pistovcakova J, Jurica J, Tomandl J, Linhart I, Sulcova A, Hadasova E: Effect of St John's wort (Hypericum perforatum) on cytochrome P-450 activity in perfused rat liver.Life Sci78 :239– 244,2005 .
   PubMed Web of Science ®Google Scholar
• Mannel M: Drug interactions with St John's Wort: Mechanisms and clinical implications.Drug Safety27 :773– 797,2004 .
   PubMed Web of Science ®Google Scholar
• Omenn G, Goodman G, Thornquist M, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL Jr, Valanis B, Williams JH, Barnhart S, Cherniack M, Brodkin CA, Hammar S: Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial.J Natl Cancer Inst88 :1550– 1559,1996 .
   PubMed Web of Science ®Google Scholar
• Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C: Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis.JAMA297 :842– 857,2007 .
   PubMed Web of Science ®Google Scholar
• Seamon M, Clauson K: Ephedra: Yesterday, DSHEA, and tomorrow–a ten year Perspective on the Dietary Supplement Health and Education Act of 1994.J Herb Pharmacother5 :67– 86,2005 .
   PubMedGoogle Scholar
• Food and Drug Administration Center for Drug Evaluation and Research Handbook: Available at www.fda.gov/cder Accessed April 21,2006 .
   Google Scholar
• Food and Drug Administration: CFR Title 21: Food and Drugs. Chapter I: Food and Drug Administration Department of Health and Human Services. Subchapter A: General. Part 56: Institutional Review Boards. Available at www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRsearch.cfm?CFRPart=56 Accessed April 21, 2006.
   Google Scholar
• PhRMA: Principles on conduct of clinical trials and communication of clinical trial results. Available at http://www.vghtpe.gov.tw/∼mre/goodexp/Fercap-Survey/PhRMA-Principles-on-Conduct-of-Clinical-Trials.pdf Accessed April 21, 2006.
   Google Scholar
• Mozaffarian D, Rimm EB: Fish intake, contaminants, and human health: evaluating the risks and the benefits.JAMA296 :1885– 1889,2006 .
   PubMed Web of Science ®Google Scholar
• GISSI-Prevenzione Investigators: Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial.Lancet354 :447– 455,1999 .
   PubMed Web of Science ®Google Scholar
• Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K: Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.Lancet369 :1090– 1098,2007 .
   PubMed Web of Science ®Google Scholar
• Burr M, Fehily A, Gilbert J, Rogers S, Holliday RM, Sweetnam PM, Elwood PC, Deadman NM: Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and Reinfarction Trial (DART).Lancet2 :757– 762,1989 .
   PubMed Web of Science ®Google Scholar
• Calder PC: n-3 fatty acids and cardiovascular disease: evidence explained and mechanisms explored.Clin Sci107 :1– 11,2004 .
   PubMed Web of Science ®Google Scholar
• Oh R: Practical applications of fish oil (omega-3 fatty acids) in primary care.J Am Board Fam Pract18 :28– 36,2005 .
   PubMedGoogle Scholar
• Miller M: Why triglycerides need to be aggressively managed: a guide for physicians.Cardiovasc Rev Rep24 :520– 526,2003 .
   Google Scholar
• Harris W: Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review.J Lipid Res30 :785– 807,1989 .
   PubMed Web of Science ®Google Scholar
• Bucher H, Hengstler P, Schindler C, Meier G: N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials.Am J Med112 :298– 304,2002 .
   PubMed Web of Science ®Google Scholar
• GISSI-HF Investigators: Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial.Lancet August 29,2008 .
   Google Scholar
• Von Schacky C, Angerer P, Kothny W, Theisen K, Mudra H: Omega-3 fatty acids and cardiovascular disease.Curr Opin Clin Nutr Metab Care10 :129– 135,2007 .
   PubMed Web of Science ®Google Scholar
• Mosca L, Banka CL, Benjamin EJ, Berra K, Bushnell C, Dolor RJ, Ganiats TG, Gomes AS, Gornik HL, Gracia C, Gulati M, Haan CK, Judelson DR, Keenan N, Kelepouris E, Michos ED, Newby LK, Oparil S, Ouyang P, Oz MC, Petitti D, Pinn VW, Redberg RF, Scott R, Sherif K, Smith SC Jr, Sopko G, Steinhorn RH, Stone NJ, Taubert KA, Todd BA, Urbina E, Wenger NK: Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update.Circulation115 :1481– 1501,2007 .
   PubMed Web of Science ®Google Scholar
• McKenney JM, Sica D: Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia.Am J Health Syst Pharm64 :595– 605,2007 .
   PubMed Web of Science ®Google Scholar
• Harris W: n-3 fatty acids and serum lipoproteins: human studies.Am J Clin Nutr65 :1645S– 1654S,1997 .
   PubMed Web of Science ®Google Scholar
• Davidson M, Stein E, Bays H, Maki K, Doyle R, Shalwitz R, Ballantyne C, Ginsberg H, on behalf of the COMBination of prescription Omega-3 with Simvastatin (COMBOS) investigators: An 8-week randomized, double-blind, placebo-controlled study of the efficacy and safety of adding prescription omega-3 fatty acids 4g/d to simvastatin 40mg/d in hypertriglyceridemic subjects.Clin Ther29 :1354– 1367,2007 .
   PubMed Web of Science ®Google Scholar
• Harris WS: Fish oil supplementation: evidence for health benefits.Cleve Clin J Med71 :208– 221,2004 .
   PubMed Web of Science ®Google Scholar
• Bryhn M, Hansteen H, Schanche T, Aakre S: The bioavailability and pharmacodynamics of different concentrations of omega-3 acid ethyl esters.Prostaglandins Leukot Essent Fatty Acids75 :19– 24,2006 .
   PubMed Web of Science ®Google Scholar
• ConsumerLab.com: Product review: omega-3 fatty acids (EPA and DHA) from fish/marine oils. Available at http://www.consumerlab.com/results/omega3.asp Accessed April 23, 2007.2006 .
   Google Scholar
• Bays HE: Safety considerations with omega-3 fatty acid therapy.Am J Cardiol99 :S35C– S43C,2007 .
   Web of Science ®Google Scholar
• Sanders T, Sullivan D, Reeve J, Thompson G: Triglyceride-lowering effect of marine polyunsaturates in patients with hypertriglyceridemia.Arteriosclerosis5 :459– 465,1985 .
   PubMedGoogle Scholar
• Zucker M, Bilyeu D, Helmkamp G, Harris W, Dujovne C: The effects of dietary fish oil on platelet function and plasma lipids in hyperlipoproteinemic and normal subjects.Atherosclerosis73 :13– 22,1988 .
   PubMed Web of Science ®Google Scholar
• Kulkarni SP, Alexander KP, Lytle B, Heiss G, Peterson ED: Long-term adherence with cardiovascular drug regimens.Am Heart J151 :185– 191,2006 .
   PubMed Web of Science ®Google Scholar
• Atwater J M-SJ, Roll DB: The USP Dietary Supplement Verification Program: Helping Pharmacists and Consumers Select Dietary Supplements.US Pharmacist30 :61– 64,2005 .
   Google Scholar
• USP Verified Dietary Supplements. vol 2007: United States Pharmacopeia,2007 .
   Google Scholar
• Burr M, Sweetnam P, Fehiley A: Letter to the Editor.Eur Heart J15 :1152– 1154,1994 .
   PubMed Web of Science ®Google Scholar
• Borthwick L: The effects of an omega-3 ethyl ester concentrate on blood lipid concentrations in patients with hyperlipidaemia.Clin Drug Invest15 :397– 404,1998 .
   PubMed Web of Science ®Google Scholar
• Chan D, Watts G, Beilin L, Redgrave T, Mori T: Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia.Diabetes51 :2377– 2386,2002 .
   PubMed Web of Science ®Google Scholar
• Grundt H, Nilsen DW, Hetland O, Aarsland T, Baksaas I, Grande T, Woie L: Improvement of serum lipids and blood pressure during intervention with n-3 fatty acids was not associated with changes in insulin levels in subjects with combined hyperlipidaemia.J Intern Med237 :249– 259,1995 .
   PubMed Web of Science ®Google Scholar
• Westphal S, Orth M, Ambrosch A, Osmundsen K, Luley C: Postprandial chylomicrons and VLDLs in severe hypertriacylglycerolemia are lowered more effectively than are chylomicron remnants after treatment with n-3 fatty acids.Am J Clin Nutr71 :914– 920,2000 .
   PubMed Web of Science ®Google Scholar
• Pownall H, Brauchi D, Kilinc C, Osmundsen K, Pao Q, Payton-Ross C, Gotto AM, Ballantyne CM: Correlation of serum triglyceride and its reduction by ω−3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins.Atherosclerosis143 :285– 297,1999 .
   PubMed Web of Science ®Google Scholar
• Mackness M, Bhatnagar D, Durrington P, Prais H, Haynes B, Morgan J, Borthwick L: Effects of a new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia.Eur J Clin Nutr48 :859– 865,1994 .
   PubMed Web of Science ®Google Scholar
• Childs M, King I, Knopp R: Divergent lipoprotein responses to fish oils with various ratios of eicosapentaenoic acid and docosahexaenoic acid.Am J Clin Nutr52 :632– 639,1990 .
   PubMed Web of Science ®Google Scholar
• Grimsgaard S, Bonaa K, Hansen J, Nordoy A: Highly purified eicosapentaenoic acid and docosahexanoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids.Am J Clin Nutr66 :649– 559,1997 .
   PubMed Web of Science ®Google Scholar
• Fish Oil Supplements.Med Lett Drugs Ther48 :59– 60,2006 .
   PubMed Web of Science ®Google Scholar
• FDA Talk Paper: FDA finalizes rules for claims on dietary supplements. Available at http://vm.cfsan.fda.gov/∼lrd/tpdsclm.html Accessed March 2,2006 .
   Google Scholar